Cheryl H Arrowsmith, PhD

Senior Scientist, Princess Margaret Cancer Centre
Keywords: p53, structural biology, structural proteomics, structural genomics, DNA damage and repair
Dr. Arrowsmith received her PhD from the University of Toronto in 1987 and post-doctoral training at Stanford University. In 1991 she started her independent research program at the Ontario Cancer Institute investigating how transcription factors recognize DNA to regulate gene expression and cell growth.
  • Epigenetics and Drug Discovery
    Epigenetics refers to heritable differences in phenotype that are due to mechanisms other than differences in DNA sequence. Epigenetics involves a dynamic interplay between DNA methylation, posttranslational modification of histones and other proteins, and noncoding RNA networks that control gene expression programs in normal and diseased cells.

    Mutations in chromatin regulatory genes and alterations of the cellular epigenome are prevalent in most cancers. Post-translational modifications (PTMs) on histone proteins serve as docking sites for chromatin-associated proteins, which in turn dictate dynamic conversion between transcriptionally active or silent chromatin states. The combinatorial nature of these modifications establishes a "histone code" which serves to expand the information present in the DNA-sequence of the genetic code. Lysine methylation is the most complex mark, and it plays a pivotal role in heterochromatin formation, transcriptional regulation and X-chromosome inactivation. Mutations or aberrant expression of proteins containing these domains often leads to deregulation of histone lysine methylation, leading to various diseases, most notably, cancer.

    We work with the Structural Genomics Consortium (SGC) to develop structure-based potent, selective, cell-active small molecule inhibitors of individual epigenetic regulatory proteins. These compounds, also referred to as chemical probes, are extremely valuable for understanding epigenetic signaling mechanisms in cells. Chemical probes are highly complementary to genetic methods and more closely mimic strategies for therapeutic translation. We are providing our epigenetic chemical probes as an Open Access resource to the biological research community to facilitate understanding of epigenetic mechanisms and to more rapidly identify and validate therapeutic targets for cancer and other diseases.
  • p53, ubiquitin signaling, and cancer
    p53 protein plays a major role in maintaining the integrity of the genome. One of its major roles in normal cells is the induction of cell cycle arrest or apoptosis in response DNA damage, by activating or repressing transcription of genes involved in these processes. Inactivation of the tumor suppressor p53 through deletion, mutation or interaction with proteins is a key step in over half of all human cancers. We are particularly interested in understanding, at the atomic levels, how various cellular proteins interact with and regulate the function of p53. Some of the proteins we have characterized include Replication Protein A (RPA), Ubiquitin Specific Protease 7 (USP7), Cullin 7 (Cul7) and Pirh2. Results from these studies have provided insight into the molecular mechanism of p53 regulation via protein-protein and protein-peptide interactions.

    Our work on ubiquitin-mediated regulation of p53 has led us to wider consideration of ubuquitylation pathways. Again in collaboration with the SGC we have studied proteins involved in chromatin ubiquitylation (UHRF1, UHRF2, Ring1b) and the entire E2 ubiquitin ligase and ubiquitin-like domain families. 
  • NMR spectroscopy and hybrid methods in structural biology
    NMR spectroscopy and x-ray crystallography are the two common techniques used to determine the structure of proteins. We have developed NMR analysis resources such as ABACUS, a protocol that analyzes networks of J-correlated spectral peptide-linked peaks and NOE spectral peaks combined with a fragment monte carlo (FMC) procedure to sequence-specifically assign the backbone and side-chain resonances of proteins. To date, this method had been used to solve over 85 protein structures deposited in the PDB. The ABACUS protocol is available for download here.

    We also employ x-ray crystallography, small angle X-ray scattering (SAXS) and chemical crosslinking as tools to characterize multidomain proteins and multiprotein complexes with hybrid computational strategies.

Related Links

Associated Program(s)
Consistent blind protein structure generation from NMR chemical shift data.
Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4685-90
Shen Y, Lange O, Delaglio F, Rossi P, Aramini JM, Liu G, Eletsky A, Wu Y, Singarapu KK, Lemak A, Ignatchenko A, Arrowsmith CH, Szyperski T, Montelione GT, Baker D, Bax A
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity.
J Biol Chem. 2008 Apr 25;283(17):11355-63
Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, McLean TH, Bochkarev A, Plotnikov AN, Vedadi M, Arrowsmith CH
Structural genomics and drug discovery: all in the family.
Curr Opin Chem Biol. 2008 Feb;12(1):32-9
Weigelt J, McBroom-Cerajewski LD, Schapira M, Zhao Y, Arrowsmith CH, Arrowmsmith CH
The solution structure of ribosomal protein S17E from Methanobacterium thermoautotrophicum: a structural homolog of the FF domain.
Protein Sci. 2008 Mar;17(3):583-8
Wu B, Yee A, Huang YJ, Ramelot TA, Cort JR, Semesi A, Jung JW, Lee W, Montelione GT, Kennedy MA, Arrowsmith CH
Solution structure of ribosomal protein L40E, a unique C4 zinc finger protein encoded by archaeon Sulfolobus solfataricus.
Protein Sci. 2008 Mar;17(3):589-96
Wu B, Lukin J, Yee A, Lemak A, Semesi A, Ramelot TA, Kennedy MA, Arrowsmith CH
The hypothetical protein Atu4866 from Agrobacterium tumefaciens adopts a streptavidin-like fold.
Protein Sci. 2008 Jan;17(1):154-8
Ai X, Semesi A, Yee A, Arrowsmith CH, Choy WY, Li SS
L3MBTL1 recognition of mono- and dimethylated histones.
Nat Struct Mol Biol. 2007 Dec;14(12):1229-30
Min J, Allali-Hassani A, Nady N, Qi C, Ouyang H, Liu Y, MacKenzie F, Vedadi M, Arrowsmith CH
Biochemical and structural characterization of a novel family of cystathionine beta-synthase domain proteins fused to a Zn ribbon-like domain.
J Mol Biol. 2008 Jan 4;375(1):301-15
Proudfoot M, Sanders SA, Singer A, Zhang R, Brown G, Binkowski A, Xu L, Lukin JA, Murzin AG, Joachimiak A, Arrowsmith CH, Edwards AM, Savchenko AV, Yakunin AF
In situ proteolysis for protein crystallization and structure determination.
Nat Methods. 2007 Dec;4(12):1019-21
Dong A, Xu X, Edwards AM, Midwest Center for Structural Genomics, Structural Genomics Consortium, Chang C, Chruszcz M, Cuff M, Cymborowski M, Di Leo R, Egorova O, Evdokimova E, Filippova E, Gu J, Guthrie J, Ignatchenko A, Joachimiak A, Klostermann N,...
CUL7 is a novel antiapoptotic oncogene.
Cancer Res. 2007 Oct 15;67(20):9616-22
Kim SS, Shago M, Kaustov L, Boutros PC, Clendening JW, Sheng Y, Trentin GA, Barsyte-Lovejoy D, Mao DY, Kay R, Jurisica I, Arrowsmith CH, Penn LZ

Pages
Senior Scientist, Princess Margaret Cancer Centre

Professor, Department of Medical Biophysics, Faculty of Medicine, University of Toronto
Chief Scientist, Structural Genomics Consortium, Toronto